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CD44v3 and v6 variant isoform expression correlates
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Summary Expression of altematively spliced CD44 isoforms has been reported to correlate with poor prognosis in human squamous cell
cancers, i.e. squamous cell cancer of the lung and cervix. The aim of this study was to evaluate whether CD44 isoform expression is a
prognostic factor in early-stage squamous cell cancer of the vulva. Seventy cases of squamous cell carcinoma of the vulva Intemational
Federation of Gynaecology and Obstetrics (FIGO) stage were examined immunohistochemically for expression of CD44 isoforms. We used
four different variant exon sequence-specific murine monoclonal antibodies to epitopes encoded by exons v3. v5, v6 and v7-8 of human
variant CD44. The correlation of CD44 expression with histological grade and disease-free and overall survival was investigated. CD44
isoforms CD44v3, CD44v5, CD44v6 and CD44v7-8 were detected in 28% (20/70), 47% (33/70), 33% (23/70) and 17% (12/70) of the tumour
samples respectively. Patients suffering from tumours expressing CD44v6 had a poorer relapse-free (log-rank test. P = 0.02) and overall
survival (log-rank test. P = 0.03). Likewise, patients suffering from tumours expressing CD44v3 had a poorer relapse-free (log-rank test,
P = 0.04) and overall survival (log-rank test, P = 0.01). Expression of CD44v5 and CD44v7-8 did not compromise the patients' outcome.
Histological grade did not correlate with CD44 isoform expression. Immunohistochemically detected expression of CD44 isoforms containing
variant exon v6 or v3 is correlated with a poor relapse-free and overall survival in FIGO stage vulvar cancer patients.
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Squamous cell cancer of the x-ulx a is a rarely encountered disease.
accounting for4c%- ofall gxnaecological malignancies. When diag-
nosed wxith vulvar cancer in an earlv stage of the disease, patients
general1v enjov a faxourable prognosis. % ith 5-xear survxial rates
of 80-90%f/ (Hacker et al. 1994). Howxever. a small subset of
patients suffering from early-stage i-ulx ar cancer are still at risk for
recurrence. Additional prognostic factors may be useful to identifx
this subgroup of high-risk patients. thus makinc them eligible for
close follow--up schemes or adjux anttherapy.
The transmembrane receptor protein CD44 belongs to the
familv of cell-surface adhesion molecules mediatinc cell-cell and
cell-matrix interactions (Underhill et al. 1992). CD44 is inxolxed
in lymphocyte functions such as cell actixation. motility. division.
adhesion to extracellular matrix and adhesion to stromal cells
(Mackax et al. 19941. CD44 proteins are encoded by a gene
located on chromosome 11. The CD44 gene comprises 19 exons.
nine of w-hich may be alternatively spliced to form additional
amino acids in the extracellular domain of the CD44 protein
(Screaton et al. 1992). Aberrant expression ofCD44 isoforms. e.g.
CD44x-6 and -7-8. indicates a loss of splice control in malianantlv
transformed cells (Salles et al. 1993).
It has been show-n that the expression ofCD44 isoforms is asso-
ciated with metastasis and poor prognosis in human malignancies
such as breast cancer. colorectal cancer and gastrointestinal
lvmphoma (Joensuu et al. 1993: Mulder et al. 1994: Kauffmann et
al. 1995). However, in sexveral human malignancies. e.g. oxvarian
cancer. expression of CD44 isoforms does not compromise the
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patients' outcome ICannistra et al 1995). CD44 isoforms associ-
ated wxith metastasis and poor prognosis may differ from other
isoforms in their abilitx to form homomultimeric complexes in the
plasma membrane of expressing cells. This may in tum increase
their affinity for extracellular matrix ligands such as hyaluronan.
The aim of this study w-as to exaluate wxhether CD44 isoform
expression is a prognostic factor in early-stage xvulxar cancer.
Therefore. ve examined the expression of CD44 isoforms
containing X ariant exons v3. x 5. 6 and x-7-8 in 70 primary -ulvar
carcinomas International Federation of Gynaecologv and
Obstetrics (FIGO) stage I.
MATERIALS AND METHODS
Sexenty patients wxith surgically treated squamous cell carcinoma
of the vulxa were included in the studv. Mean age w-as 62 (ran2e
39-77) y-ears. The patients x-ere selected randomlx. A minimum of
6 months offollow-up was required for inclusion into the studv.
From 1980 to 1989 patients undervent radical xulxectomy or
radical tumour excision. Diagnosis xwas established preoperatixely
by punch biopsy. Patients with lesions with a depth of invasion of
no more than 1 mm and clinically negatixe groin lymph nodes
receixed no post-operatixe therapy. Patients with a depth of inxa-
sion ofmore than 1 mm and clinically- negatixe groin lyNmph nodes
underx-ent adjuxvant post-operatixe garoin irradiation. Groin lymph
node dissection w-as performed in patients with clinically suspi-
cious groin lymph nodes. In cases ofly mph node metastases. post-
operatixe radiotherapy w-as applied. The therapy scheme w-as
performed according to Kucera et al (1988).
Histological stagincg was performed according to the current
International Union Against Cancer (UICC) classification and
10911092 C Tempfer etal
1.0 -
No CD44v6 expression
CD44v6 expression
oi
0
2
:3
0
0 20 40 60 80
Time since initial treatment (months)
100
No CD44v3 expression
CD44v3 expression
100 0 20 40 60 80
Time since initial treatment (months)
Figure 1 Kaplan-Meier analys regarding overall survival of patients
suffering from tumours with or without expression of splice variant CD44v6
clinical staging according to the FIGO classification (Hermanek et
al. 1992). All cases were reviewed by an experienced pathologist.
blinded to the clinical data of the patients Histologically. 37
tumours were graded as well differentiated. 23 as moderately
differentiated and ten as poorly differentiated.
Immunohistochemistry
Paraffin sections were soaked in xylene to remove paraffin and rehy-
drated in a graded alcohol series (100-70%). To recover antigenicity
we used the Antigen Retrieval System' (Bio Genex. San Ramon.
CA. USA) twice for 20 min in a microwave at 600 W power (HM
146. Elektra Bregenz. Schwaz. Austria) and then the sections were
washed in O mM phosphate-buffered saline (PBS) (pH 7.6). Four
different variant exon sequence-specific murine monoclonal anti-
bodies specific for the epitope encoded by exon v3 ofhuman variant
CD44 (CD44-3. clone 3G5. R&D Systems. Minneapolis. MA.
USA). exon v5 (CD44v5. clone VFF-8. Bender Co.. Vienna.
Austria). exon v6 (CD44v6. clone VFF-7. Bender) and exons v7-8
(CD44v7-8. clone VFF-17. Bender) were used. The primary anti-
body was diluted in serum-PBS and the sections were incubated for
60 mim and then incubated for 30 min with biotinylated anti-mouse
and anti-rabbit link antibody (Dako LSAB 2 Kit Dako. Carpinteria.
CA. USA). After nrnsing in PBS the sections were coated for 10 min
with streptavidin conjugated to alkaline phosphatase. The sections
were then rinsed in PBS. incubated with fast red chromogen (naph-
thol phosphate substrate in Tris buffer, fast red chromogen tablets
5 mg. Bio Genex. San Ramon. CA. USA) and then washed with
distilled water. The sections were finally counterstained with haema-
toxylin and mounted. Staining of > 10% of the tumour cells was
interpreted as positive staining of < 10% of the tumour cells was
interpreted as negative. Two independent readers analysed the
samples. In four cases discordant results were obtained. These slides
were re-evaluated together and a consensus was reached.
Figure 2 Kapban-Mer analysis regarding overall survival of patients
suffering from tumours with or without expression of splice variant CD44v3
Positive control. The positive control slide wvas prepared from
epidermal tissue. known to contain the antigen. In the positive
control tissue all monoclonal antibodies stained similarlv.
Negative control. The negative control slide was prepared from
the same tissue block as the specimen. Instead of the primary
antibody we used a non-immune rabbit serum (Dako code no.
X902).
In order to rule out that the difference in staining with the
different antibodies is the result of differences in affinity rather
than the result of differential expression on tumour cells. we
prepared a dilution series probed on positive controls. e.g. skin
samples. The dilution factors ranged from 1:50 to 1:400. For
CD44v3. CD44v5. CD44v6 and CD447 -8. optimal staining was
found at a dilution factor of 1:100. 1:200. 1:00 and 1:50 of the
basic solution (IgG concentration lOO1 g ml-' respectively. In
order to ensure adequate specificity of the monoclonal antibodies
when applied to paraffm-embedded tissue samples. we stained
frozen and parffin-embedded samples of normal vulvar skin side
by side with all anti-CD44 variant antibodies. Staining Awas
comparable in all cases.
Statistics
The chi-square test was used when appropriate. Survival probabili-
ties were calculated by the product limit method of Kaplan and
Meier (Kaplan and Meier. 1958). Differences between groups were
tested using the log-rank test. The results were analysed for the end
point of oserall and relapse-free survival. Survival times ofpatients
still alive or relapse-free were censored with the last follow-up
date. P-values < 0.05 were considered statistically significant. The
Kendall Tau b-correlation coefficient was used to assess the correla-
tion between the expression ofdifferent CD44 isoforms. The BMDP
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Figure 3 Kaplan-Meier analysis regarding overall survival of patients
suffering from tumours with or without expression of splice vanant CD44v5
statistical software system (BMDP Statistical Software. Los
Angeles. CA. 1990) was used to perform the calculations.
RESULTS
CD44 isoforms CD44v3. CD44v5. CD44v6 and CD44v7-8 were
detected by means of immunohistochemistry in 28% (20/70). 47%
(33no). 33% (23/7O) and 17% (12/70) of the tumour samples
respectively. We observed a membrane-bound staining pattern in
all specimens positive for the investigated CD44 isoforms. All
patients showed complete remission after completion of therapy.
The range of follow-up was 6.5-86 months (median 56 months).
Thirteen patients developed recurrence of disease after 5-73
months (median 35 months). During the observation penrod. 12
patients died of tumour progression. CD44v6 expression was
found in patients with and without recurrence in 14 and 9 cases
respectively. Patients suffering from tumours expressing CD44v6
had a poorer relapse-free (log-rank test. P = 0.02) and overall
surnival (log-rank test. P = 0.03. Figure 1). CD44v3 expression
was found in patients with and without recurrence in 12 and 8
cases respectively. Patients suffering from tumours expressing
CD44v3 had a poorer relapse-free (log-rank test. P = 0.04) and
overall survival (log-rank test. P = 0.01. Figure 2).
Survival analysis for the whole population showed no significant
prognostic value for CD44v5 (log-rank test. P = 0.8. Figure 3) and
CD44v7-8 (log-rank test. P = 0.9. Figure 4). Correlation coefficients
for CD44v3/CD44v5. CD44v3/CD44v6. CD44v3/CD44v7-8.
CD44v5/CD44v6. CD44v5/CD44v7-8 and CD44v6/CD44v7-8
were 0.24. 0.01. 0.11. 0.21. 0.12 and 0.05 respectively.
Patients with poorly differentiated tumours had a shorter overall
survival than patients with moderately and highly differentiated
tumours (log-rank test. P = 0.02). We found no correlation
between the expression of CD44 isoforms and histological grade
of the tumours.
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Figure 4 Kaplan-Meter analysis regarding overall survival of paients
suffering from tumours with or without expression of splice variant CD44v7-8
DISCUSSION
The expression of cell-surface glycoproteins encoded by CD44
variant exons has been shown to be associated with poorprognosis
in human malignancies. e.g. breast. cervical and colorectal cancer
(Mulder et al. 1994: Kainz et al. 1995: Kauffmann et al. 1995). We
assessed the expression pattem and prognostic impact of CD44
splice variant proteins CD44v3. CD44v5. v6 and v7-8 in 70
pnmary vulvar carcinomas.
Because of the rarity of the disease. few data on CD44 expres-
sion in vulvar cancer have been published so far. The presence of a
prominent fibromyxoid stromal response (PFSR) is correlated
with clitoral involvement. ulcerative growth and regional lymph
node metastasis in vulvar cancer. Ambros et al (1996) have
reported PFSR to be strongly correlated with high CD44 expres-
sion. Therefore. it may be hypothesized that CD44 plays a role in
vulvar tumorigenesis by altering the hyaluronate metabolism of
the vulvar stroma.
In our series vulvar cancer samples showed frequent expression
of CD44v3. CD44vS and CD44v6. whereas CD44v7-8 was only
expressed in a small number of cases. This expression pattern is in
accordance with previously reported data on squamous cell carci-
nomas of the cervix (Kainz et al. 1995).
In all our specimens we obserned a membrane-bound staining
pattern for all four investigated CD44 isoforms. This observation is
in accordance with previously reported data on CD44 stainingy
pattems in other human malignomas (Salmi et al. 1993: Kainz et al.
1995). The immunohistochemical approach of detecting CD44
expression must be viewed with care because ofpossible underesti-
mation ofmembrane molecule expression as a result ofembedding
procedures. However. in recent studies an excellent correlation
between the detection ofCD44 isoforms by immrunohistochemistrs
and reverse transcription PCR was reported (Dall et al. 1995).
In two recent pilot studies involving 30 and 25 cases of primarv
vulvar cancer of different stages. CD44v3 and CD44v6 have been
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descnrbed as new prognostic factors (Tempfer et al. 1996a. b). It
has to be stated that a total of nine patients described in these
previous studies are also incorporated in the present Investigation.
The aim of the present study was to evaluate whether CD44
isoform expression may be used as an adverse prognosticator in a
homogeneous collective ofpatients with early-stage vulvarcancer.
We were able to show that expression of CD44 isoforms
containing variant exons v6 or v3 is correlated with a poor prog-
nosis. Patients whose tumours revealed expression of CD44v6 or
CD44v3 showed a significantly poorer overall and relapse-free
survival.
These data indicate that CD44 isoform expression is an early
event in vulvar carcinogenesis. It is a shortcoming of this study
that, because of the study period before the introduction of a
surgical staging system by FIGO in 1988 (Anonymous. 1989). no
groin dissection was performed. Therefore it cannot be ruled out
that micrometastases may have been present in patients included
in the study. This has to be taken into account when interpreting
the results ofthis study.
The assessment ofCD44 isoform expression could be ofclinical
value in selecting patients forclose follow-up schemes orindeciding
about adjuvant therapy in patients suffering from low-stage vulvar
cancer. In summary. the results ofthispreliminary study indicate that
the evaluation ofCD44expression may be helpful in individualizing
the management ofearly-stage vulvar cancer.
REFERENCES
Anonymous (1989) FIGO stages - 1988 revision (announcement Gvnecol Oncol
35:125
Ambros RA. Kallakutn B. Malfetano J and Mihm M (1996) Cvmok-ine. cell adhesion
receptor. and tumour suppressor gene expression in vulvar squamous
carcnoma: correlation with prominent fibromvxoid stromal response. IntJ
Gvnecol Pathol 15: 320-325
Cannistra SA. Abu-Jawdeh G and NiloffJ (1995) CD44 variant expression is a
common feature ofepithelial ovarian cancer lack ofassociation %ith standard
prognostic factors. J Clin Oncol 13: 1912-1921
Dall P. Heider KH. Sinn HP. Skroch Angel P. AdolfG and Kauffmann M (1995)
Comparison ofimmunohistochemistry and RT-PCR for detection ofCD44v-
expression. a new prognostic factor in human breast cancer. IntJ Cancer60:
471-477
Hacker NF (1994) Vulvar cancer. In Practical Gvnecologic Oncolop-. 2nd edn.
Berek JS and Hacker NT (eds). pp. 403-425. illiams and Wilkins: Baltimore
Hermanek P and Sobin L 1992) LICC T. 'M Classification ofMalignant Tumours.
4th edn. 2nd rev. Springer-Verlag: Berlin.
Herrlich P. Zoller M. Pals ST and Ponta H ( 1993 CD44 splice -ariants: metastases
meet lymphocvtes. Immunol Today 14: 395-399
Joensuu H. Ristarnaki R. Klemi PJ and Jalkanen S(1993) Lymphocyte homing
receptor (CD44) expression is associated with poor prognosis in
gastrointestinal lymphoma BrJ Cancer 68: 428-432
Kainz C. Kohlberger P. Sliutz G. Tempfer C. Heinzl H and Reinthaller A (1995)
Splice variants ofCD44 in human cervical cancer stage lB to [lB. Gynecol
Oncol 57: 383-387
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete
observations. J Am StarAssoc 53: 457-481
Kaufmann M. Heider KH. Sinn HP. von Minckwitz G. Ponta H and Herrlich P
(1995 CD44 variant exon epitopes in primnar breast cancer and length of
survival. Lancet 345: 615-619
Kucera H and Weghaupt K ( 1988 The elecrosurgical operation ofvulvar carcinoma
with post-operative irradiation ofinguinal l mph nodes. Gynecol Oncol 29:
158-167
Mackay CR. Terpe H. Stauder R. Marston W: Stark- H and Guenthert U (1994)
Expression and modulation ofCD44 variant isoforms in humans. J Cell Biol
124: 71-82
Mulder JW. Kruvt PM. Se-nath NI. Oostine J. Seldenrijk CA and Weidema WAT
(1994) Colorectal cancer prognosis and expression ofexon-v6-containine
CD44 proteins. Lancet 344: 1470-1472
Salles G. Zain M. Jiang W. Boussiotis V and Shipp M (1993) Alternatively spliced
CD44 tanscripts in diffuse large cell lInpbomas: characterization and
comparison with normal activated B cells and epithelial malignancies. Blood
82: 3539-3547
Salmi M. Gron Vrta K. Sointu P. Greman R. KalimoH and Jalkanen S 1993>
Regulated expression ofexon v6 containing isoforms ofCD44 in man:
downregulation during malignan transformation oftumours of squamocellular
origin. J Cell Biol 122: 431-442
Screaton GR. Bell MV. Jackson DG. Cornelis FB. GCerth U and Bell ni (1992)
Genomic struture ofDNA encoding the lymphocyte homing receptor CD44
reVeals at least 12 alternatisely spliced exons. Proc .Val Acad Sci USA 489:
12160-12164
Smith CU. Patton JG and Nadal Ginard B (1989) Alternatie splicing in the control
ofgene expression. Annu Rev Genet 23: 527-577
Tempfer C. Gitsch G. Haeusler G. Reinthaller A. Koelbl H and Kainz C 1996a)
Prognostc value ofimmunohistochemicallv detected CD44 expression in
patients uith carcinoma ofthe vulva Cancer 78: 273-277
Tempfer C. Gitsch G. Hanzal E. Reinthaller A. Koelbl H and Kainz C ( 1996b)
Expression ofthe adhesion molecule CD44-3 is a prognostic factor in vulvar
carcinoma Anticancer Res 16: 2029-2032
Underhill C (1992) CD44: the hyaluronan receptor. J Cell Sci 103:293-98
British Journal ofCancer (1998) 78(8), 1091-1094 0 CancerResearch Campaign 1998